SCHEMBL2167264

SCHEMBL2167264

CCc1ccc(CN2CC3C(C2)C3C(=O)Nc2ccc(Cc3ccccc3)cc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.52
SMN1; SMN2 Q16637 3/20 0.51
HTT P42858 2/20 0.51
TP53 P04637 2/20 0.51
NPSR1 Q6W5P4 1/20 0.51
ALDH1A1 P00352 4/20 0.50
LMNA P02545 2/20 0.50
GAA P10253 1/20 0.50
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
POLB P06746 2/20 0.48
S1PR1 P21453 1/20 0.48
S1PR5 Q9H228 1/20 0.48
PKM P14618 1/20 0.46
MAPT P10636 1/20 0.46
STAT1 P42224 1/20 0.46
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
REV1 Q9UBZ9 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29215851 0.86 POLB (0.58) FAAHTP53NPC1RAB9APOLB
SCHEMBL30268809 0.86 POLB (0.58) FAAHTP53NPC1RAB9APOLB
SCHEMBL4421587 0.83 ALDH1A1 (0.52) FAAHSMN1; SMN2HTTTP53NPSR1
SCHEMBL4413751 0.83 RAB9A (0.50) FAAHSMN1; SMN2HTTTP53NPSR1
SCHEMBL19971614 0.81 S1PR5 (0.50) FAAHS1PR1S1PR5
SCHEMBL19971613 0.81 S1PR5 (0.50) FAAHS1PR1S1PR5
SCHEMBL18517410 0.81 S1PR5 (0.50) FAAHS1PR1S1PR5
SCHEMBL4431183 0.79 SMN1; SMN2 (0.44) FAAHSMN1; SMN2HTTTP53NPSR1
SCHEMBL4430245 0.78 ALDH1A1 (0.46) FAAHSMN1; SMN2HTTTP53ALDH1A1
SCHEMBL27035777 0.75 S1PR5 (0.50) FAAHS1PR1S1PR5KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP claimed
JP-4732354-B2 2011-07-27 JP claimed
EP-1680124-A4 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2009-05-13 EP claimed
JP-2007508374-A 2007-04-05 JP claimed
EP-1680124-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS Pfizer Products Incorporated (US) 2006-07-19 EP claimed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US claimed
WO-2005037216-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PRODUCTS INC. (US) 2005-04-28 WO claimed
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP disclosed
US-7473787-B2 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC (US) 2009-01-06 US disclosed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors SLC6A5, SLC1A5, SLC6A3 FAAH 2866/4885SMN1; SMN2 4003/4885HTT 1090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.